Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
September 06 2019 - 4:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two
poster presentations at the 23rd Annual Heart Failure Society of
America (HFSA) Scientific Meeting in Philadelphia. The posters will
be presented on September 13, 2019 and September 14, 2019, and will
include the design of METEORIC-HF (
Multicenter
Exercise
Tolerance
Evaluation of
Omecamtiv Mecarbil
Related to
Increased
Contractility in
Heart
Failure), the second Phase 3 clinical trial
of omecamtiv mecarbil, and data from the Phase 1 study of
CK-3773274 (CK-274), a novel cardiac myosin inhibitor, discovered
by company scientists, in development for the potential treatment
of HCM which may result from increased cardiac contractility.
Title: Multicenter Exercise
Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased
Contractility in Heart FailureDate: September 13,
2019 Session: Clinical Trial
RowTime: 6:15 – 7:15 PMPoster
Number: CTR-602
Title: A First in Human Study
of the Selective Cardiac Myosin Inhibitor,
CK-3773274Poster Presenter: Fady
I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of
Research & DevelopmentDate: September 14, 2019
Session: General Poster Session
IITime: 6:15 – 7:15 PMPoster
Number: 210
About CK-274
CK-274 is a novel, oral, small molecule cardiac
myosin inhibitor that company scientists discovered independent of
its collaborations. CK-274 arose from an extensive chemical
optimization program conducted with careful attention to
therapeutic index and pharmacokinetic properties that may translate
into next-in-class potential in clinical development. CK-274 was
purposely designed to reduce the hypercontractility that is
associated with hypertrophic cardiomyopathy (HCM). In preclinical
models, CK-274 reduces myocardial contractility by binding directly
to cardiac myosin at a distinct and selective allosteric binding
site, thereby preventing myosin from entering a force producing
state. CK-274 reduces the number of active actin-myosin cross
bridges during each cardiac cycle and consequently reduces
myocardial contractility. This mechanism of action may be
therapeutically effective in conditions characterized by excessive
hypercontractility, such as HCM.
The preclinical pharmacokinetics of CK-274 were
characterized evaluated and optimized for potential rapid onset,
ease of titration and rapid symptom relief in the clinical setting.
The initial focus of the development program for CK-274 will
include an extensive characterization of its PK/PD relationship as
has been a hallmark of Cytokinetics’ industry-leading development
programs in muscle pharmacology. The overall development program
will assess the potential of CK‑274 to improve exercise capacity
and relieve symptoms in patients with hyperdynamic ventricular
contraction due to HCM.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and best-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
clinical trials program in patients with heart failure including
GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide
license to develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization in Europe and
certain other countries. Cytokinetics is collaborating with
Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a fast
skeletal muscle troponin activator (FSTA) for diseases of
neuromuscular dysfunction, including SMA and ALS. Astellas holds an
exclusive worldwide license to develop and commercialize
reldesemtiv. Licenses held by Amgen and Astellas are subject to
specified co-development and co-commercialization rights of
Cytokinetics. Cytokinetics is also developing CK-274, a novel
cardiac myosin inhibitor that company scientists discovered
independent of its collaborations, for the potential treatment of
hypertrophic cardiomyopathies. Cytokinetics continues its over
20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to the timing, design
and results of Cytokinetics’ Phase 1 clinical trial of CK-274; the
potential benefits of CK-274; Cytokinetics’ and its partners’
research and development activities; the timing of enrollment of
patients in Cytokinetics’ and its partners’ clinical trials; the
design, timing, results, significance and utility of preclinical
and clinical results; and the properties and potential benefits of
Cytokinetics’ drug candidates. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approvals for trial commencement,
progression or product sale or manufacturing, or production of
Cytokinetics’ drug candidates that could slow or prevent clinical
development or product approval; patient enrollment for or conduct
of clinical trials may be difficult or delayed; Cytokinetics’ drug
candidates may have adverse side effects or inadequate therapeutic
efficacy; the FDA or foreign regulatory agencies may
delay or limit Cytokinetics’ or its partners’ ability to conduct
clinical trials; Cytokinetics may be unable to obtain or
maintain patent or trade secret protection for its intellectual
property; Cytokinetics’ partners decisions with respect to research
and development activities; standards of care may change, rendering
Cytokinetics’ drug candidates obsolete; competitive products or
alternative therapies may be developed by others for the treatment
of indications Cytokinetics’ drug candidates and potential drug
candidates may target; and risks and uncertainties relating to the
timing and receipt of payments from its partners, including
milestones and royalties on future potential product sales under
Cytokinetics’ collaboration agreements with such partners. For
further information regarding these and other risks related to
Cytokinetics’ business, investors should consult Cytokinetics’
filings with the Securities and Exchange Commission.
Contact:CytokineticsDiane WeiserVice President, Corporate
Communications, Investor Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024